ES2078251T3 - Sistema para la distribucion regulada de agentes activos y proceso para su preparacion. - Google Patents

Sistema para la distribucion regulada de agentes activos y proceso para su preparacion.

Info

Publication number
ES2078251T3
ES2078251T3 ES90101888T ES90101888T ES2078251T3 ES 2078251 T3 ES2078251 T3 ES 2078251T3 ES 90101888 T ES90101888 T ES 90101888T ES 90101888 T ES90101888 T ES 90101888T ES 2078251 T3 ES2078251 T3 ES 2078251T3
Authority
ES
Spain
Prior art keywords
preparation
pharmaceutical
realization
agents
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90101888T
Other languages
English (en)
Inventor
Udo Prof Dr Sc Nat Wenzel
Jurgen Doz Dr Sc Med D Metzner
Thomas Dr Rosin
Halvor Dr Med Jaeger
Zoser B Dr Rer Nat Salama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INT PHARMA AGENTUR
Original Assignee
INT PHARMA AGENTUR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25748261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2078251(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DD89325354A external-priority patent/DD295760A5/de
Priority claimed from DE19893932987 external-priority patent/DE3932987A1/de
Application filed by INT PHARMA AGENTUR filed Critical INT PHARMA AGENTUR
Application granted granted Critical
Publication of ES2078251T3 publication Critical patent/ES2078251T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Filling Or Discharging Of Gas Storage Vessels (AREA)
  • Operation Control Of Excavators (AREA)
  • External Artificial Organs (AREA)

Abstract

EL INVENTO SE REFIERE A UN SISTEMA PARA CONTROLAR LA REALIZACION DE AGENTES ACTIVOS Y PROCESO PARA SU PREPARACION, PREFERIBLEMENTE UNA PREPARACION FARMACEUTICA ADMINISTRABLE POR VIA ORAL, ESPECIALMENTE SOLUBLES, AGENTES FARMACEUTICOS TENIENDO SIEMPRE UN AGENTE ACTIVO CAUSADO POR UN PROCESO DE CONVECTIVO. EL SISTEMA DEL INVENTO ES SIMILAR EN EFECTIVIDAD EN LA TERAPEUTICA INTRAVENOSA COMO POR EJEMPLO LA REALIZACION COMPLETA DE UN AGENTE ACTIVO DE UN PREPARADO FARMACEUTICO PARA PERIODOS DE PRACTICAS TERAPEUTICAS Y PSICOLOGICAS CAUSADAS POR PROCESOS CONVECTIVOS. ESTO LLEVA A UN NIVEL CONSTANTE DE LA SANGRE QUE GARANTIZA EL EFECTO DE LARGA DURACION DE LA DROGA MIENTRAS QUE REDUCE LOS EFECTOS ADVERSOS Y MEJORA LA TOLERANCIA LOCAL DEL TRACTO GASTROINTESTINAL AL MISMO TIEMPO. CON DICHA COMPOSICION DE LA PREPARACION FARMACEUTICA Y EL PROCESO DE ESTA PREPARACION PERJUDICA LA REALIZACION DE LOS AGENTES FARMACEUTICOS QUE NO SON USUALES EN EL CASO DE LA REALIZACION DEL AGENTE FARMACEUTICO, Y LA PRESENTE REALIZACION SE PODRA HACER EN UN CORTO PERIODO DE TIEMPO.
ES90101888T 1989-01-31 1990-01-31 Sistema para la distribucion regulada de agentes activos y proceso para su preparacion. Expired - Lifetime ES2078251T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DD89325354A DD295760A5 (de) 1989-01-31 1989-01-31 Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
DE19893932987 DE3932987A1 (de) 1989-10-03 1989-10-03 System fuer die kontrollierte freisetzung von wirkstoffen und verfahren zu seiner herstellung

Publications (1)

Publication Number Publication Date
ES2078251T3 true ES2078251T3 (es) 1995-12-16

Family

ID=25748261

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90101888T Expired - Lifetime ES2078251T3 (es) 1989-01-31 1990-01-31 Sistema para la distribucion regulada de agentes activos y proceso para su preparacion.

Country Status (13)

Country Link
EP (1) EP0381181B1 (es)
JP (1) JP2885858B2 (es)
AT (1) ATE126052T1 (es)
AU (1) AU641136B2 (es)
CA (1) CA2009045A1 (es)
DE (1) DE69021405T2 (es)
DK (1) DK0381181T3 (es)
ES (1) ES2078251T3 (es)
FI (1) FI900470A7 (es)
GR (1) GR3017861T3 (es)
HU (1) HU205851B (es)
IE (1) IE69174B1 (es)
NO (1) NO301520B1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ238867A (en) * 1990-07-12 1993-08-26 Alza Corp Dosage form for delayed release comprising pharmaceutically active substance and a drug-release hindering means and a second composition which imbibes fluid, expands, and ejects the active substance from the device
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
WO1996019974A1 (en) * 1994-12-27 1996-07-04 Kanebo, Ltd. Sustained-release preparation
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US6074669A (en) * 1997-01-20 2000-06-13 Ranbaxy Laboratories Limited Controlled drug delivery system for diltiazem
JP4848101B2 (ja) * 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
EP1482914B1 (en) * 2002-03-11 2015-04-22 Novartis AG Implantable drug delivery device for the eye
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
GB2150434B (en) * 1983-12-01 1987-11-04 Alza Corp Constant rate release systems
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
DE3769707D1 (de) * 1986-06-17 1991-06-06 Recordati Chem Pharm Therapeutisches system mit geregelter wirkstoffabgabe.
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form

Also Published As

Publication number Publication date
IE69174B1 (en) 1996-08-07
DE69021405T2 (de) 1996-04-11
NO900428L (no) 1990-08-01
HU205851B (en) 1992-07-28
HUT53284A (en) 1990-10-28
JP2885858B2 (ja) 1999-04-26
IE900336L (en) 1990-07-31
HU900591D0 (en) 1990-04-28
EP0381181A2 (en) 1990-08-08
CA2009045A1 (en) 1990-07-31
DE69021405D1 (de) 1995-09-14
NO301520B1 (no) 1997-11-10
EP0381181A3 (en) 1991-09-18
DK0381181T3 (da) 1995-10-30
FI900470A0 (fi) 1990-01-30
NO900428D0 (no) 1990-01-30
ATE126052T1 (de) 1995-08-15
FI900470A7 (fi) 1990-08-01
EP0381181B1 (en) 1995-08-09
JPH02282324A (ja) 1990-11-19
GR3017861T3 (en) 1996-01-31
AU641136B2 (en) 1993-09-16
AU4898890A (en) 1990-08-09

Similar Documents

Publication Publication Date Title
AR053680A1 (es) Composicion
NO953278D0 (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
PT828500E (pt) Utilizacao de flavanolignanos para a preparacao de medicamentos com actividade antiproliferativa no utero ovarios e mama
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
ES2002089T3 (es) Nuevas formulaciones farmaceuticas con liberacion programada que contienen antiflogisticos.
GT199900203A (es) Composiciones de celecoxib.
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
DE69803360D1 (de) Anwendungsformen zur behandlung der männlichen erektilen dysfunktion
DE69213010D1 (de) Verwendung eines Bakteriozin antibiotischen Agenten zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden.
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
ES2178048T3 (es) Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis.
PA8485601A1 (es) Azalidas de 13 miembros y su uso como agentes antibioticos.
NO884391L (no) Legemiddel-lipidsystemer med lav toksisitet.
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
BR0316279A (pt) Compostos orgânicos
ES2186207T3 (es) Metodo para preparacion de formulaciones farmaceuticas.
UA49789C2 (uk) Застосування димеру лізоциму як лікарського засобу для інгібування біосинтезу фактора некрозу пухлини, спосіб лікування та профілактики захворювань (варіанти), фармацевтична композиція (варіанти), застосування димеру лізоциму як лікарського засобу для профілактики або лікування сніду
MX9207344A (es) Formulaciones mejoradas que tienen mejoradores hidrofobicos de penetracion transdermica y metodo para proveerla.
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
UY26835A1 (es) Agente para inhibir la adhesión de la flora patogénica de la piel
ES2087178T3 (es) Disulfato de ws7622a, procedimiento para su preparacion y su uso.
SU1029451A1 (ru) Антибактериальное средство

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 381181

Country of ref document: ES